Botox® was licensed for the treatment of chronic migraine in July 2010 by the Medicines and Healthcare products Regulatory Agency (MHRA). Chronic migraine is defined as headaches occurring on 15 or more days each month, at least half of which have migrainous features. Botox® has not been shown to be effective for any other headache type (e.g. episodic migraine, tension-type headache, cluster headache) as yet.
Studies in the treatment of migraine have shown a decrease in the incidence and severity of headaches for a period of 3 to 4 months after an injection of BOTOX®, along with a reduction in the use of painkillers. Some people respond well after only a single treatment session, while others improve after repeated injections.
The current standard is injections every 12 weeks however it is not unusual to vary the duration between treatments in some patients. It is generally worthwhile having at least two treatment sessions to assess treatment response. If individuals have not responded by two to three treatment sessions it is generally considered that the individual is a non-responder.
Treatment available at